


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
“TOFACITINIB CITRATE TABLET”
OBTAINED DRUG REGISTRATION CERTIFICATE

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has obtained a drug registration certificate from the National Medical Products Administration of China for another product of “Tofacitib Citrate Tablet” (Product specification: 5mg; Certificate no.: 2021S00528). The product was filed as a Chemicals Category 4 drug and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Tofacitib Citrate is a new oral protein tyrosine kinase inhibitor indicated for adult patients with moderate to severe active rheumatoid arthritis who are inadequately treated by or intolerant of methotrexate. The approval of this product will provide an alternative drug option for rheumatoid arthritis patients in China.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 10 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.